Guardant Health sees stock jump after FDA approval for Guardant360 Liquid CDx
Reading Time: 3 minutes
FDA approvals for Guardant360 tests provide new momentum in May. The release of Guardant360 Liquid CDx propels the stock to multi-year highs. Revenue growth reached 48% in the first quarter, marking the highest percentage increase in the last five years. The screening business around "Shield" grew by over 600%. Management raised the annual revenue forecast to 32 to 34% and again expects strong growth in the screening segment. Guardant Health (GH) focuses as a medical services and analysis laboratory on liquid biopsy tests, which...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
